Elite Pharmaceuticals, Inc. (ELTP)
OTCMKTS · Delayed Price · Currency is USD
0.400
0.00 (0.00%)
Mar 9, 2026, 2:45 PM EST

Elite Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 2020 - 2016
Market Capitalization
430465157293562
Upgrade
Market Cap Growth
-19.07%195.83%434.24%-16.81%-42.59%1.75%
Upgrade
Enterprise Value
415468159273161
Upgrade
Last Close Price
0.400.430.150.030.030.06
Upgrade
PE Ratio
11.20-7.818.263.9712.10
Upgrade
PS Ratio
3.075.532.770.861.102.42
Upgrade
PB Ratio
5.358.682.731.011.403.81
Upgrade
P/TBV Ratio
5.378.732.741.031.433.92
Upgrade
P/FCF Ratio
24.9379.70--5.8821.50
Upgrade
P/OCF Ratio
23.2062.33-8.815.4319.27
Upgrade
EV/Sales Ratio
2.965.562.810.800.962.40
Upgrade
EV/EBITDA Ratio
7.6920.4313.095.254.9417.86
Upgrade
EV/EBIT Ratio
8.0222.0514.756.926.1128.90
Upgrade
EV/FCF Ratio
24.0580.19--5.1521.24
Upgrade
Debt / Equity Ratio
0.080.200.200.130.110.15
Upgrade
Debt / EBITDA Ratio
0.110.460.950.730.430.66
Upgrade
Debt / FCF Ratio
0.351.87--0.460.83
Upgrade
Net Debt / Equity Ratio
-0.19-0.010.08-0.14-0.23-0.05
Upgrade
Net Debt / EBITDA Ratio
-0.28-0.020.38-0.75-0.92-0.24
Upgrade
Net Debt / FCF Ratio
-0.87-0.07-1.141.65-0.96-0.28
Upgrade
Asset Turnover
1.290.930.910.901.050.99
Upgrade
Inventory Turnover
3.033.012.692.162.972.95
Upgrade
Quick Ratio
5.283.422.041.401.731.15
Upgrade
Current Ratio
7.344.883.072.752.822.10
Upgrade
Return on Equity (ROE)
74.36%-7.77%46.47%13.15%43.01%37.96%
Upgrade
Return on Assets (ROA)
29.75%14.72%10.83%6.52%10.33%5.14%
Upgrade
Return on Invested Capital (ROIC)
76.25%36.77%24.74%15.95%29.14%14.57%
Upgrade
Return on Capital Employed (ROCE)
45.60%25.10%15.30%12.00%17.80%10.30%
Upgrade
Earnings Yield
10.10%-0.93%12.80%12.11%25.18%8.27%
Upgrade
FCF Yield
4.01%1.26%-2.57%-8.15%17.00%4.65%
Upgrade
Buyback Yield / Dilution
-4.95%-4.40%-1.02%-0.23%-7.17%5.06%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.